1. Home
  2. EMBC vs TRVI Comparison

EMBC vs TRVI Comparison

Compare EMBC & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EMBC
  • TRVI
  • Stock Information
  • Founded
  • EMBC 1924
  • TRVI 2011
  • Country
  • EMBC United States
  • TRVI United States
  • Employees
  • EMBC N/A
  • TRVI N/A
  • Industry
  • EMBC Medical/Dental Instruments
  • TRVI Biotechnology: Pharmaceutical Preparations
  • Sector
  • EMBC Health Care
  • TRVI Health Care
  • Exchange
  • EMBC Nasdaq
  • TRVI Nasdaq
  • Market Cap
  • EMBC 788.4M
  • TRVI 725.7M
  • IPO Year
  • EMBC N/A
  • TRVI 2019
  • Fundamental
  • Price
  • EMBC $15.23
  • TRVI $8.07
  • Analyst Decision
  • EMBC Buy
  • TRVI Strong Buy
  • Analyst Count
  • EMBC 2
  • TRVI 9
  • Target Price
  • EMBC $18.50
  • TRVI $20.72
  • AVG Volume (30 Days)
  • EMBC 488.5K
  • TRVI 3.1M
  • Earning Date
  • EMBC 08-08-2025
  • TRVI 11-05-2025
  • Dividend Yield
  • EMBC 3.98%
  • TRVI N/A
  • EPS Growth
  • EMBC 18.26
  • TRVI N/A
  • EPS
  • EMBC 1.42
  • TRVI N/A
  • Revenue
  • EMBC $1,102,500,000.00
  • TRVI N/A
  • Revenue This Year
  • EMBC N/A
  • TRVI N/A
  • Revenue Next Year
  • EMBC N/A
  • TRVI N/A
  • P/E Ratio
  • EMBC $10.62
  • TRVI N/A
  • Revenue Growth
  • EMBC N/A
  • TRVI N/A
  • 52 Week Low
  • EMBC $9.20
  • TRVI $2.36
  • 52 Week High
  • EMBC $21.48
  • TRVI $9.92
  • Technical
  • Relative Strength Index (RSI)
  • EMBC 66.50
  • TRVI 53.07
  • Support Level
  • EMBC $14.92
  • TRVI $7.65
  • Resistance Level
  • EMBC $15.44
  • TRVI $8.28
  • Average True Range (ATR)
  • EMBC 0.50
  • TRVI 0.69
  • MACD
  • EMBC -0.08
  • TRVI 0.02
  • Stochastic Oscillator
  • EMBC 84.31
  • TRVI 37.96

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Share on Social Networks: